Drug Information

Drug General Information
Drug ID
D0S4KJ
Former ID
DNCL002245
Drug Name
KHK-2866
Drug Type
Antibody
Indication Ovarian cancer [ICD9: 183; ICD10:C56] Phase 1 [523323]
Company
Kyowa Hakko Kirin Pharma
Target and Pathway
Target(s) HB-EGF Target Info [523323]
KEGG Pathway ErbB signaling pathway
GnRH signaling pathway
Estrogen signaling pathway
Epithelial cell signaling in Helicobacter pylori infection
Proteoglycans in cancer
NetPath Pathway IL5 Signaling Pathway
IL1 Signaling Pathway
EGFR1 Signaling Pathway
TNFalpha Signaling Pathway
PANTHER Pathway EGF receptor signaling pathway
CCKR signaling map ST
Pathway Interaction Database ErbB4 signaling events
LPA receptor mediated events
Plasma membrane estrogen receptor signaling
ErbB receptor signaling network
Reactome SHC1 events in ERBB2 signaling
PI3K events in ERBB4 signaling
SHC1 events in ERBB4 signaling
Nuclear signaling by ERBB4
PIP3 activates AKT signaling
GRB2 events in ERBB2 signaling
PI3K events in ERBB2 signaling
EGFR Transactivation by Gastrin
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascade
WikiPathways ErbB Signaling Pathway
Hypertrophy Model
NRF2 pathway
Nuclear Receptors Meta-Pathway
IL1 and megakaryotyces in obesity
Signaling by ERBB4
Signaling by ERBB2
Gastrin-CREB signalling pathway via PKC and MAPK
PIP3 activates AKT signaling
References
Ref 523323ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
Ref 523323ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.